News Headlines Article

Researchers: Medivation’s failed Alzheimer’s drug deserves another shot
San Francisco Business Times

Medivation Inc.’s failed Alzheimer’s drug Dimebon deserves a second chance, a group of researchers say. Dimebon in March 2010 flamed out in a Phase III trial that disappointed Alzheimer’s disease patients and their advocates, leading San Francisco-based Medivation (NASDAQ: MDVN) to squash a planned space expansion and lay off employees.